Compare OPAL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | QNCX |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 19.9M |
| IPO Year | 2021 | 2019 |
| Metric | OPAL | QNCX |
|---|---|---|
| Price | $2.06 | $1.20 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $2.72 | N/A |
| AVG Volume (30 Days) | 147.9K | ★ 1.2M |
| Earning Date | 05-11-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $348,975,000.00 | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | ★ N/A | $0.43 |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $0.08 |
| 52 Week High | $4.08 | $4.55 |
| Indicator | OPAL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 32.94 | 57.91 |
| Support Level | $1.65 | $1.17 |
| Resistance Level | $2.53 | $1.50 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 17.00 | 17.21 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.